Raloxifene Hydrochloride Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 60 mg
Reference Brands: Evista (USA/EU)
Category:
Women's Health
Raloxifene Hydrochloride is available in Tablets
and strengths such as 60 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Raloxifene Hydrochloride is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Raloxifene Hydrochloride can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Raloxifene hydrochloride is a selective estrogen receptor modulator (SERM) used primarily in the prevention and treatment of osteoporosis in postmenopausal women and in patients receiving long-term glucocorticoid therapy. Marketed under the brand name Evista, it is an oral medication that exhibits tissue-selective activity, functioning as an estrogen agonist in bone and liver while acting as an antagonist in breast and uterine tissue. This selective mechanism allows raloxifene hydrochloride to increase bone mineral density, reduce bone resorption and turnover, and improve lipid metabolism by lowering total and LDL cholesterol levels, without stimulating breast or endometrial tissue.
In addition to its bone-protective effects, raloxifene hydrochloride has an anti-proliferative effect on estrogen-sensitive breast cancer, making it valuable in reducing breast cancer risk in high-risk postmenopausal women. Although bisphosphonates are generally preferred for osteoporosis, raloxifene is an effective alternative for patients who require additional benefits in breast cancer risk reduction. Its mechanism involves binding to estrogen receptors, forming a ligand-receptor complex that regulates estrogen-responsive genes differently depending on the tissue type, thereby providing both agonist and antagonist effects as needed for optimal therapeutic outcomes.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing